Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gadoxetic acid
- Development stage
- Approved
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gadoxetic acid (marketed as Eovist in the US and Primovist in Europe) is a gadolinium-based, hepatocyte-specific paramagnetic contrast agent used in magnetic resonance imaging (MRI) of the liver. It combines the properties of a conventional extracellular fluid contrast agent with those of a hepatobiliary agent. Gadoxetic acid is selectively taken up by functioning hepatocytes via organic anion transporting polypeptides (OATP1B1 and OATP1B3) and subsequently excreted into the bile via multidrug resistance-associated protein 2 (MRP2). This dual-phase enhancement allows for both dynamic perfusion imaging and delayed hepatobiliary phase imaging, significantly improving the detection, characterization, and differentiation of focal liver lesions, such as hepatocellular carcinoma (HCC) and liver metastases, from non-hepatocellular lesions.
- Brand names
- EovistPrimovist
- Other names
- Gd-EOB-DPTAGd-EOB-DTPAMRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)gadolinium-EOB-DTPAgadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acidgadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acidgadoxetategadoxetate disodiumgadoxetic acid disodium
02
Targets
ABCC2 (ATP-binding cassette sub-family C member 2)OATP1B1 (Organic anion transporting polypeptide 1B1)SLCO1B3 (Organic anion transporting polypeptide 1B3)
Beyond the preview
Go deeper on gadoxetic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gadoxetic acid.